KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Cash: 2009-2024

Historic Change in Cash for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $133.9 million.

  • Acadia Pharmaceuticals' Change in Cash rose 122.96% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.5 million, marking a year-over-year increase of 72.71%. This contributed to the annual value of $133.9 million for FY2024, which is 81.45% up from last year.
  • As of FY2024, Acadia Pharmaceuticals' Change in Cash stood at $133.9 million, which was up 81.45% from $73.8 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Change in Cash high stood at $137.3 million for FY2020, and its period low was -$178.6 million during FY2021.
  • Moreover, its 3-year median value for Change in Cash was $73.8 million (2023), whereas its average is $58.4 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Change in Cash plummeted by 230.05% in 2021, and later soared by 326.49% in 2023.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Change in Cash stood at $137.3 million in 2020, then plummeted by 230.05% to -$178.6 million in 2021, then spiked by 81.75% to -$32.6 million in 2022, then soared by 326.49% to $73.8 million in 2023, then surged by 81.45% to $133.9 million in 2024.